Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | NCF1 | P14598 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | SMO | Q99835 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30937462 | 1.00 | ALDH1A1 (0.59) | ALDH1A1HPGDUSP2TP53MAPK1 | |
| SCHEMBL113679 | 0.84 | ALDH1A1 (0.55) | ALDH1A1HPGDUSP2MAPK1KMT2A | |
| SCHEMBL5919531 | 0.84 | ALDH1A1 (0.61) | ALDH1A1HPGDUSP2TP53MAPK1 | |
| SCHEMBL27926749 | 0.81 | MGLL (0.46) | ALDH1A1HPGDMAPK1KMT2ASMN1; SMN2 | |
| SCHEMBL28235242 | 0.81 | MGLL (0.46) | ALDH1A1HPGDMAPK1KMT2ASMN1; SMN2 | |
| SCHEMBL9565829 | 0.81 | AKR1C3 (0.62) | ALDH1A1HPGDUSP2TP53MAPK1 | |
| SCHEMBL3436305 | 0.81 | ALDH1A1 (0.76) | ALDH1A1KMT2AHTTNCF1TSHR | |
| SCHEMBL3801245 | 0.81 | GAA (0.65) | ALDH1A1KMT2ASMN1; SMN2MEN1LMNA | |
| SCHEMBL30062550 | 0.80 | GPR119 (0.52) | ALDH1A1TP53KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL1928396 | 0.80 | GPR119 (0.52) | ALDH1A1TP53KMT2ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9926286-B2 | Vortioxetine intermediate and synthesis process thereof | SHANGHAI SYNCORES TECHNOLOGIES INC. LTD. (CN) | 2018-03-27 | — | — | US | disclosed |
| US-9926286-B2 | Vortioxetine intermediate and synthesis process thereof | SHANGHAI SYNCORES TECHNOLOGIES INC. LTD. (CN) | 2018-03-27 | — | — | US | disclosed |
| US-20170088530-A1 | NEW VORTIOXETINE INTERMEDIATE AND SYNTHESIS PROCESS THEREOF | SHANGHAI SYNCORES TECHNOLOGIES INC. LTD. (CN) | 2017-03-30 | — | — | US | disclosed |
| US-20170088530-A1 | NEW VORTIOXETINE INTERMEDIATE AND SYNTHESIS PROCESS THEREOF | SHANGHAI SYNCORES TECHNOLOGIES INC. LTD. (CN) | 2017-03-30 | — | — | US | disclosed |
| EP-3141543-A1 | NEW VORTIOXETINE INTERMEDIATE AND SYNTHESIS PROCESS THEREOF | Shanghai Syncores Technologies, Inc. (CN) | 2017-03-15 | — | — | EP | disclosed |
| CN-100400523-C | Substituted piperazines, (1,4) diaza * class and 2, 5-diazabicyclo (2.2.1) heptanes as histamine H1 and/or H3 antagonists or histamine H3 reverse antagonists | GLAXO GROUP LTD (GB) | 2008-07-09 | — | — | CN | disclosed |
| CN-101070309-A | Substituted piperazines as histamine H1 and/or H3 antagonists or histamine H3 reverse antagonists, (1, 4) diazabi and 2, 5-diazabicyclo (2.2.1) heptanes | GLAXO GROUP LTD (GB) | 2007-11-14 | — | — | CN | disclosed |
| CN-1726201-A | Substituted piperazines, (1,4) diaza * class and 2, 5-diazabicyclo (2.2.1) heptanes as histamine H1 and/or H3 antagonists or histamine H3 reverse antagonists | GLAXO GROUP LTD (GB) | 2006-01-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088530-A1 | NEW VORTIOXETINE INTERMEDIATE AND SYNTHESIS PROCESS THEREOF | CYP3A4, CYP4B1, COMT | ALDH1A1 249/4885HPGD 1270/4885USP2 1848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.